Patents by Inventor Ioana Kloos

Ioana Kloos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
    Patent number: 9492423
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: November 15, 2016
    Assignee: PHARMACYCLICS LLC
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian, Ioana Kloos, Stephane Depil
  • ASSOCIATION BETWEEN N-HYDROXY-4-BENZAMIDE AND FOLFOX
    Publication number: 20150038513
    Abstract: Association between N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-yl-carbonylamino]ethoxy}benzamide of formula (I): an addition salt thereof with a pharmaceutically acceptable acid or base, and FOLFOX. Medicaments.
    Type: Application
    Filed: July 3, 2012
    Publication date: February 5, 2015
    Inventors: Stéphane Depil, Anne Jacquet-Bescond, Ioana Kloos, Anne-Laure Sarry, Sriram Balasubramanian, Joseph Buggy
  • ADMINISTRATION REGIME FOR N-HYDROXY-4-BENZAMIDE
    Publication number: 20150024040
    Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Inventors: Ioana Kloos, Renata Robert, Anne Jacquet-Bescond, Stéphane Depil, Marylore Chenel, Sylvain Fouliard, Sriram Balasubramanian
  • FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF
    Publication number: 20140341989
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Application
    Filed: September 13, 2011
    Publication date: November 20, 2014
    Applicants: PHARMACYCLICS, INC.
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian, Ioana Kloos, Stephane Depil
  • Administration regime for N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2- ylcarbonylamino]ethoxy}benzamide
    Patent number: 8883199
    Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterized in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: November 11, 2014
    Assignees: Les Laboratoires Servier, Pharmacyclics, Inc.
    Inventors: Ioana Kloos, Renata Robert, Anne Jacquet-Bescond, Stephane Depil, Marylore Chenel, Sylvain Fouliard, Sriram Balasubramanian
  • ADMINISTRATION REGIME FOR N-HYDROXY-4-BENZAMIDE
    Publication number: 20130064880
    Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.
    Type: Application
    Filed: September 6, 2012
    Publication date: March 14, 2013
    Applicants: LES LABORATOIRES SERVIER
    Inventors: Ioana Kloos, Renata Robert, Anne Jacquet-Bescond, Stéphane Depil, Marylore Chenel, Sylvain Fouliard, Sriram Balasubramanian